Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. held its 2025 second extraordinary general meeting where several resolutions were passed. These included the approval of a Share Option Scheme and an RSU Scheme, both receiving overwhelming support from shareholders. The meeting was conducted in compliance with relevant laws and regulations, and the resolutions are expected to enhance the company’s operational flexibility and incentivize service providers, potentially strengthening its market position.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and production of monoclonal antibody drugs. The company is involved in the biopharmaceutical industry, providing innovative therapies for various diseases, with a market focus on both domestic and international markets.
Average Trading Volume: 1,292,493
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.24B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.